LGND: Ligand Pharmaceuticals Incorporated Stocks News on November 27, 2025

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 92% This Year

LGND

Investor's Business Daily

7 days ago

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 92% This Year

3 Prominent Stocks Estimated To Be Trading At Up To 38.9% Below Intrinsic Value

LGND

Simply Wall St.

5 months ago

3 Prominent Stocks Estimated To Be Trading At Up To 38.9% Below Intrinsic Value

3 Stocks Estimated To Be Up To 48.8% Undervalued Offering A 32.6% Discount Opportunity

LGND

Simply Wall St.

5 months ago

3 Stocks Estimated To Be Up To 48.8% Undervalued Offering A 32.6% Discount Opportunity

LGND

MT Newswires

5 months ago

Channel Therapeutics to Implement 10-for-1 Reverse Stock Split

Three Stocks That May Be Trading Below Their Estimated Value In June 2025

LGND

Simply Wall St.

5 months ago

Three Stocks That May Be Trading Below Their Estimated Value In June 2025

LGND

Argus Research

5 months ago

LGND: Raising target price to $124.00

3 Stocks Estimated To Be Trading Up To 48.7% Below Intrinsic Value

LGND

Simply Wall St.

5 months ago

3 Stocks Estimated To Be Trading Up To 48.7% Below Intrinsic Value

Incyte And Two Other Stocks That May Be Priced Below Their Estimated Value

LGND

Simply Wall St.

5 months ago

Incyte And Two Other Stocks That May Be Priced Below Their Estimated Value

3 Companies That May Be Trading Below Their Estimated Value

LGND

Simply Wall St.

6 months ago

3 Companies That May Be Trading Below Their Estimated Value

Ligand Announces 2025 Investor Day in New York City

LGND

GlobeNewswire

6 months ago

Ligand Announces 2025 Investor Day in New York City

LGND

Argus Research

6 months ago

LGND: Raising target price to $119.00

LGND

Argus Research

6 months ago

LGND: Lowering target price to $110.00

LGND

MT Newswires

6 months ago

Ligand Pharmaceuticals Pick of the Week at Smart Insider Following CEO, CFO Stock Purchases

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

LGND

GlobeNewswire

6 months ago

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

LGND

Argus Research

6 months ago

Daily – Vickers Top Buyers & Sellers for 05/14/2025

LGND

Argus Research

6 months ago

LGND: Raising target price to $111.00

LGND

Zacks Small Cap Research

7 months ago

LGND: 1Q:25 Results

Ligand Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

LGND

Simply Wall St.

7 months ago

Ligand Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

LGND

MT Newswires

7 months ago

Oppenheimer Adjusts Ligand Pharmaceuticals Price Target to $145 From $142, Maintains Outperform Rating

LGND

GuruFocus.com

7 months ago

Ligand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...

LGND

MT Newswires

7 months ago

Ligand Pharmaceuticals Q1 Core Adjusted Earnings, Revenue Increase; Shares Up Pre-Bell

LGND

Associated Press Finance

7 months ago

Ligand: Q1 Earnings Snapshot

Ligand Reports First Quarter 2025 Financial Results

LGND

GlobeNewswire

7 months ago

Ligand Reports First Quarter 2025 Financial Results

LGND

GuruFocus.com

7 months ago

Ligand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Report Preview: What To Look For

LGND

Argus Research

7 months ago

LGND: Lowering target price to $108.00

Ligand to Participate in May Investor Conferences

LGND

GlobeNewswire

7 months ago

Ligand to Participate in May Investor Conferences

LGND

Simply Wall St.

7 months ago

Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 49% Discount?

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

LGND

GlobeNewswire

7 months ago

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

LGND

Zacks Small Cap Research

7 months ago

LGND: Pelthos To Become Public Company

LGND

Argus Research

7 months ago

LGND: What does Argus have to say about LGND?

LGND

MT Newswires

7 months ago

Sector Update: Health Care Stocks Softer Thursday Afternoon

LGND

MT Newswires

7 months ago

Update: Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics

LGND

MT Newswires

7 months ago

Top Midday Gainers

LGND

MT Newswires

7 months ago

Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

LGND

GlobeNewswire

7 months ago

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

LGND

Benzinga

7 months ago

EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity

LGND

Argus Research

7 months ago

LGND: Raising target price to $112.00

LGND

MT Newswires

8 months ago

Stifel Initiates Ligand Pharmaceuticals at Buy With $143 Price Target

LGND

Argus Research

8 months ago

LGND: Lowering target price to $102.00

LGND

Argus Research

8 months ago

LGND: Lowering target price to $110.00

LGND

Argus Research

8 months ago

LGND: Raising target price to $115.00

Top March 2025 Stocks Estimated To Be Trading Below Their Intrinsic Value

LGND

Simply Wall St.

9 months ago

Top March 2025 Stocks Estimated To Be Trading Below Their Intrinsic Value

LGND

Argus Research

9 months ago

LGND: Lowering target price to $121.00

Ligand to Participate in March Investor Conferences

LGND

GlobeNewswire

9 months ago

Ligand to Participate in March Investor Conferences

LGND

Zacks Small Cap Research

9 months ago

LGND: First Steps into Cell & Gene Therapy

LGND

MT Newswires

9 months ago

Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $142 From $151, Maintains Outperform Rating

LGND

MT Newswires

9 months ago

RBC Raises Price Target on Ligand Pharmaceuticals to $155 From $143, Keeps Outperform Rating

LGND

GuruFocus.com

9 months ago

Ligand Pharmaceuticals Inc (LGND) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

LGND

MT Newswires

9 months ago

Ligand Pharmaceuticals' Q4 Core Adjusted Net Income, Total Revenue Rise; 2025 Guidance Set

LGND

Associated Press Finance

9 months ago

Ligand: Q4 Earnings Snapshot

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

LGND

GlobeNewswire

9 months ago

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

LGND

GuruFocus.com

9 months ago

Ligand Pharmaceuticals Inc (LGND) Q4 2024: Everything You Need To Know Ahead Of Earnings

LGND

Argus Research

9 months ago

LGND: Lowering target price to $125.00

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

LGND

GlobeNewswire

9 months ago

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

LGND

Argus Research

9 months ago

LGND: Raising target price to $126.00

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

LGND

Business Wire

9 months ago

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

LGND

Business Wire

10 months ago

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

LGND

Argus Research

10 months ago

LGND: Lowering target price to $123.00

LGND

Argus Research

10 months ago

LGND: Raising target price to $124.00

LGND

Argus Research

10 months ago

LGND: Raising target price to $123.00

LGND

Argus Research

10 months ago

LGND: Lowering target price to $114.00

LGND

Zacks Small Cap Research

10 months ago

Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025

LGND

Simply Wall St.

a year ago

Ligand Pharmaceuticals (NASDAQ:LGND) shareholders have earned a 59% return over the last year

LGND

Argus Research

a year ago

LGND: Lowering target price to $119.00

LGND

Argus Research

a year ago

LGND: Raising target price to $126.00

LGND

Zacks Small Cap Research

a year ago

LGND: 2025 View Calls for 17% Topline Growth

Ligand price target raised to $151 from $135 at Oppenheimer

LGND

TipRanks

a year ago

Ligand price target raised to $151 from $135 at Oppenheimer

LGND

MT Newswires

a year ago

Oppenheimer Adjusts Ligand Pharmaceuticals Price Target to $151 From $135, Maintains Outperform Rating

LGND

MT Newswires

a year ago

RBC Raises Price Target on Ligand Pharmaceuticals to $143 From $141, Keeps Outperform Rating

LGND

Argus Research

a year ago

LGND: Lowering target price to $125.00

LGND

MT Newswires

a year ago

Ligand Pharmaceuticals Issues 2025 Guidance; 2024 Forecast Reaffirmed

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

LGND

Business Wire

a year ago

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

LGND

Argus Research

a year ago

LGND: Lowering target price to $126.00

LGND

MT Newswires

a year ago

RBC Lifts Price Target on Ligand Pharmaceuticals to $141 From $140, Keeps Outperform Rating

LGND

Simply Wall St.

a year ago

Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings

Ligand to Present at Stifel 2024 Healthcare Conference

LGND

Business Wire

a year ago

Ligand to Present at Stifel 2024 Healthcare Conference

LGND

Argus Research

a year ago

LGND: Raising target price to $127.00

LGND

Zacks Small Cap Research

a year ago

LGND: 3Q Sales Surprise to the Upside

Ligand Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

LGND

Simply Wall St.

a year ago

Ligand Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

LGND

Simply Wall St.

a year ago

Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Intrinsic Value Is Potentially 99% Above Its Share Price

LGND

GuruFocus.com

a year ago

Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

LGND

MT Newswires

a year ago

Sector Update: Health Care Stocks Rise Late Afternoon

LGND

MT Newswires

a year ago

Ligand Shares Rise After Q3 Tops Expectations, Guidance Raised

LGND

Associated Press Finance

a year ago

Ligand: Q3 Earnings Snapshot

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

LGND

Business Wire

a year ago

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

LGND

GuruFocus.com

a year ago

Ligand Pharmaceuticals Inc (LGND) Q3 2024: Everything You Need To Know Ahead Of Earnings

LGND

Argus Research

a year ago

LGND: Lowering target price to $117.00

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

LGND

Business Wire

a year ago

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

LGND

Business Wire

a year ago

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

LGND

GlobeNewswire

a year ago

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

LGND

GuruFocus.com

a year ago

Ligand Pharmaceuticals Inc (LGND) Q2 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...

LGND

Zacks Small Cap Research

a year ago

LGND: Initiating Coverage – A Prince Among Royalty

LGND

Argus Research

a year ago

LGND: Raising target price to $108.00

LGND

MT Newswires

a year ago

Oppenheimer Initiates Ligand Pharmaceuticals at Outperform With $135 Price Target

LGND

Simply Wall St.

a year ago

Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum?

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

LGND

Business Wire

a year ago

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

LGND

Argus Research

a year ago

LGND: Raising target price to $112.00

Insider Sale: President & COO Matthew Korenberg Sells 18,858 Shares of Ligand ...

LGND

GuruFocus.com

a year ago

Insider Sale: President & COO Matthew Korenberg Sells 18,858 Shares of Ligand ...

LGND

Argus Research

a year ago

LGND: Raising target price to $110.00

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference

LGND

Business Wire

a year ago

Latest Ligand Pharmaceuticals Incorporated (LGND) News on November 27, 2025

Share on Social Networks: